To the full analysis
Baxter International stock: growth
BAXBaxter International reported $11.24B in revenue for fiscal 2025, up 5.7% on the prior year, up 7.9% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
0.4%
per year from 2006 to 2025, per share 1.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
−8.2%
per year from 2006 to 2025, per share −7.1%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −0.7% | 1.2% | 0.4% |
| Revenue per share | −0.9% | 1.8% | 1.7% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −22.5% | −9.3% | −8.2% |
| Free cash flow per share | −22.7% | −8.8% | −7.1% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $10.38B | $1.4B | $1.66B |
| 2007 | $11.26B | $1.71B | $1.61B |
| 2008 | $12.35B | $2.01B | $1.56B |
| 2009 | $12.56B | $2.21B | $1.9B |
| 2010 | $12.84B | $1.42B | $2.04B |
| 2011 | $13.89B | $2.22B | $1.86B |
| 2012 | $13.94B | $2.33B | $1.95B |
| 2013 | $9.41B | $2.01B | $2.49B |
| 2014 | $10.72B | $2.5B | $2.29B |
| 2015 | $9.97B | $968M | $860M |
| 2016 | $10.16B | $4.97B | $935M |
| 2017 | $10.58B | $602M | $1.1B |
| 2018 | $11.1B | $1.55B | $1.36B |
| 2019 | $11.36B | $1B | $1.41B |
| 2020 | $11.67B | $1.1B | $1.16B |
| 2021 | $12.15B | $1.28B | $1.53B |
| 2022 | $10.06B | −$2.43B | $576M |
| 2023 | $10.36B | $2.66B | $1.29B |
| 2024 | $10.64B | −$649M | $559M |
| 2025 | $11.24B | −$957M | $323M |
Revenue by segment
How Baxter International Inc. makes its money and how that has shifted. Names are as the company reports them.
- Medical Products And Therapies47%
- Healthcare Systems and Technologies27%
- Pharmaceuticals22%
- Other3%
“Other” combines smaller and former segments with revenue the company does not assign to a segment. Names as reported, with abbreviations spelled out for the largest companies.
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| Medical Products And Therapies | $5.21B | $5.3B | 47.1% |
| Healthcare Systems and Technologies | $2.95B | $3.07B | 27.3% |
| Pharmaceuticals | $2.41B | $2.49B | 22.2% |
| Other | $0 | $381M | 3.4% |
| Total revenue | $10.64B | $11.24B | 100% |
Revenue by region
Where Baxter International Inc. generates its revenue.
- United States54%
- Western Europe, Canada, Japan, Australia and New Zealand33%
- EMEA12%
Figures as a table
| 2024 | 2025 | Share 2025 | |
|---|---|---|---|
| United States | $5.85B | $6.12B | 54.4% |
| Western Europe, Canada, Japan, Australia and New Zealand | $3.44B | $3.73B | 33.2% |
| EMEA | $1.35B | $1.39B | 12.4% |
| Total revenue | $10.64B | $11.24B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 May 2024)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.